IN8bio (NASDAQ:INAB – Free Report) had its price target cut by HC Wainwright from $8.00 to $6.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.
IN8bio Stock Performance
Shares of INAB opened at $0.23 on Friday. IN8bio has a 1 year low of $0.21 and a 1 year high of $1.74. The company has a market cap of $18.32 million, a price-to-earnings ratio of -0.30 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a fifty day moving average of $0.28 and a 200-day moving average of $0.30.
IN8bio (NASDAQ:INAB – Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. As a group, equities analysts anticipate that IN8bio will post -0.56 earnings per share for the current year.
Hedge Funds Weigh In On IN8bio
IN8bio Company Profile
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Featured Stories
- Five stocks we like better than IN8bio
- Using the MarketBeat Stock Split Calculator
- How to Build the Ultimate Everything ETF Portfolio
- Insider Trades May Not Tell You What You Think
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Invest in the FAANG Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.